Next to identifying the F-box protein FBXL2 as a tumor suppressor [8], the NEDD8 inhibitor pevonedistat showed some additional benefit when combined with azacytidine in AML patients in clinical trials [9], and is undergoing further investigation in AML and further hematological malignancies. This evidence concerns the gene FBXL2 and acute myeloid leukemia.